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Epithelial ovarian cancer (EOC) is a complex disease, with multiple histological subtypes
recognized. There have been major advances in the understanding of the cellular and mol-
ecular biology of this human malignancy, however the survival rate of women with EOC
has changed little since platinum-based-treatment was introduced more than 30 years ago.
Since 2006, an increasing number of studies have indicated an essential role for microRNAs
(miRNAs) in ovarian-cancer tumorigenesis. Several miRNA profiling studies have shown
that they associate with different aspects of ovarian cancer (tumor subtype, stage, histo-
logical grade, prognosis, and therapy resistance) and pointed to a critical role for miRNAs in
the pathogenesis and progression of EOC. In this review, we discuss the current data con-
cerning the accumulating evidence of the modulated expression of miRNAs in EOC, their
role in diagnosis, prognosis, and prediction of response to therapy. Given the heterogeneity
of this disease, it is likely that increases in long-term survival might be also achieved by
translating the recent insights of miRNAs involvement in EOC into novel targeted therapies
that will have a major impact on the management of ovarian cancer.
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INTRODUCTION
Among United States women, ovarian cancer is the sixth most
common cancer and the second most common gynecologic can-
cer (after endometrial cancer) (Parkin et al., 2002). Ovarian-cancer
occurs in 1 of 2500 postmenopausal women in the United States
and accounts for 5–6% of all cancer-related deaths (Jemal et al.,
2008). The 5-year survival rate of ovarian-cancer ranges from 30 to
90%, depending on the spread of disease at diagnosis. When ovar-
ian cancer is diagnosed at early stages, the survival rate is close to
90%; unfortunately, the vast majority of patients is identified when
they have late-stage disease (Goff et al., 2000). This is primarily
because ovarian cancer has few early or specific symptoms shared
with many more common gastrointestinal, genitourinary, and
gynecological conditions and have not yet proved useful for early
diagnosis. Patients diagnosed with advanced disease are managed
with surgical cytoreduction and chemotherapy, but many experi-
ence resistance to chemotherapy and relapse, yielding an overall
5-year survival rate of 10–30%. At the cellular and molecular lev-
els, ovarian cancers are remarkably heterogeneous (Boxes 1 and 2).
The normal ovary is a complex tissue with several distinct com-
ponents. Although ovarian cancers can develop from germ cells or
granulosa-theca cells, more than 90% of ovarian cancers have an
epithelial histology and are thought to arise from cells that cover
the ovarian surface or that line subsurface inclusion cysts (Feeley
and Wells, 2001). One of the major disappointments in the field of
ovarian-cancer research is the failure of currently established ther-
apies to induce a cure at diagnosis, even in chemosensitive tumors.
Efforts have been made to cure ovarian cancer over the past decade
using different classes of chemotherapeutic agents in various com-
binations, dosages, and schedules to overcome chemoresistance
following front-line paclitaxel–platinum treatment. Our improved
understanding of the underlying biology of ovarian tumor etiol-
ogy and chemoresistance has led to the development of molecular
targeted therapies. Many small-molecule inhibitors and mono-
clonal antibodies that target multiple crucial cancer characteristics,
including cell growth and survival, angiogenesis, and metastases
are now entering clinical trials (Figure 1). However, new efforts
are needed to identify new and better markers/therapeutics to aid
the diagnostic and curative process of ovarian cancer.
MicroRNAs (miRNAs) are single-stranded RNAs (ssRNAs)
∼19–25 nt in length that negatively regulate gene expression by
translation inhibition or messenger RNA (mRNA) degradation,
through base-pairing to partially complementary sites on the tar-
get mRNAs, usually in the 3′ untranslated region (UTR) (Garofalo
and Croce, 2011; Mendell and Olson, 2012). Bioinformatic analy-
ses predict the existence of ∼1000 miRNAs in the human genome
capable to regulate up to 60% of all human transcriptome. Due to
their highly abundance, conservation and tissue specific expres-
sion miRNAs play key roles in almost all biological processes,
including gene regulation, cell developmental control, and the
development of various diseases, such as cancer. Dysregulation
of miRNA expression appears to play a fundamental role in the
onset, progression and dissemination of cancers, and replacement
of down-regulated miRNAs in tumor cells results in a positive ther-
apeutic response (Croce, 2009). Accumulating data have shown
that miRNAs are also aberrantly expressed in ovarian cancer and
can be associated with tumor subtypes, clinical outcomes, and
chemoresistance, indicating that miRNAs may be involved in ovar-
ian tumorigenesis and progression. In the following review, we
will discuss recent progresses in understanding the functions of
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Box 1 Ovarian-cancer subtypes.
Despite the controversy surrounding the histogenesis of ovarian cancers, it is widely believed today that most OECs (90%) arise from the
ovarian surface epithelium. OECs are now classified in several histologic subtypes with distinctive risk factors, genetic abnormalities, and
oncologic pathways that partly determine biologic behavior, response to chemotherapy, and prognosis. OECs develop from simple flattened
epithelial cells into four different main histotypes that resemble the well-differentiated cells of the fallopian tube (serous, the most common
with 7 out of every 10 epithelial ovarian cancers), endometrium (endometrioid, 1 in 20 epithelial ovarian cancers), endocervix (mucinous,
1 in 10 epithelial ovarian cancers), and cells that form nests within the vagina (clear cells, the least common subtype of epithelial ovarian
cancer with just 3 in 100 cases). A significant proportion of endometrioid carcinomas and clear-cell carcinomas is associated with preex-
isting endometriosis. Serous carcinoma can be classify in high-grade (HGSC) and low-grade tumors (LGSC). Most HGSCs are biologically
aggressive neoplasms, and they often manifest at an advanced stage, with up to 85% of patients with ovarian serous carcinoma presenting
with widespread peritoneal metastases. Up to 80% of HGSCs show initial response to platinum-based chemotherapy, but about 70%
may demonstrate recurrence. LGSC behaves like a slow-growing indolent neoplasm (presumably due to lack of p53 mutations) and has
a better prognosis. Unlike HGSCs, recurrent LGSCs have high extreme drug resistance to paclitaxel, carboplatin, and cisplatin (33–69%
of cases), but low drug resistance to etoposide and doxorubicin. Endometrioid carcinomas are platinum-sensitive tumors and, owing to
low-grade early-stage disease and better chemotherapy sensitivity, are associated with the most favorable prognosis among all subtypes of
EOCs. Mucinous neoplasms account for 10–15% of all ovarian tumors and up to 80% of mucinous neoplasms are benign cystadenomas.
Clear-cell carcinomas are biologically aggressive neoplasms despite their being diagnosed at early stages. In this case, recurrence following
surgery is common. Clear-cells and mucinous cancers generally do not respond as well as serous and endometrioid cancers to platinum-
and taxane-based chemotherapy.
Box 2 Ovarian-cancer genomic alteration.
At molecular levels, the gene expression profiles of the different ovarian-cancer histotypes correlate with their morphological counterparts
in normal tissues. HGSC is frequently characterized by mutations or loss of heterozygosity of p53 and genetic-epigenetic silencing of BRCA
genes (∼80% of cases). Instead, LGSCs are characterized by frequent mutations of K-ras, BRAF, and erb-B2 (HER-2) genes. In endometrioid
carcinomas CTNNB1 mutations (38–50% of cases), PTEN mutations (20%), and microsatellite instability (up to 19%) are commonly seen.
In mucinous carcinomas, K-ras mutations are common and constitute an early event in tumorigenesis. Moreover, HER-2 gene amplification
is seen in 15–20% of tumors. Clear-cell carcinomas are the most common histologic subtype characterized by the highest frequency of
PI3KCA mutations: 33% of these carcinomas demonstrate activating mutations of PI3KCA. Mutations involving the PIK3CA gene lead
to activation of the PI3K/AKT pathway, resulting in improved cell survival and invasion. The different histotypes of EOCs have also been
correlated with the abnormal re-expression of homeobox genes (HOX) that are normally expressed during the formation of gynecological
organs. HOXA9 is highly expressed in serous, HOX 10 in endometrioid, and HOXA11 in mucinous ovarian cancer.The vast majority of OECs
(90%) are sporadic, with the remainder being inherited as part of hereditary ovarian-cancer syndromes. Germline mutations of BRCA1
and BRCA2 tumor-suppressor genes are responsible for most hereditary ovarian cancers (90–95%). The lifetime risk of developing ovarian
cancer is about 20–50% in patients carrying BRCA mutations.
miRNAs in ovarian cancer and their possible use as diagnostic and
prognostic markers, and eventually as new targets or tools of a
specific therapy.
MICRORNA IN CANCER
Over the last 10 years, we have seen an enormous number of
studies concerning the role of miRNAs in cancer (8461 PubMed
hits on February 2013). Despite the large variety both in terms
of the diseases and the experimental approaches taken, many
essential and general principles of miRNA activity in human
cancer have been defined. miRNAs activity is firstly related to
redundancy: each miRNA exerts its full functional effects by reg-
ulating hundreds or thousands of targets (Mendell and Olson,
2012). To complicate the scenario, many miRNAs exist in fami-
lies with similar seed sequences, and many of them from different
families are co-expressed as a large clusters to amplify and max-
imize their inhibitory activity. Redundancy can also be found
at the level of the target mRNAs where different miRNAs may
also repress the same target. The second important aspect of
miRNA/cancer relationship has been revealed by the application
of the high-throughput technologies which have allowed the iden-
tification of cancer-specific miRNA fingerprints in all type of
human cancer (Calin and Croce, 2006; Croce, 2009). In general, the
expression of miRNAs in malignant cells is significantly different
from that of normal counterpart cells and facilitate the stratifi-
cation of cancer and the identification of the tissue of origin for
poorly differentiated tumors. Some of the most commonly dys-
regulated miRNAs in cancer are summarized in Table 1. The third
essential aspect of miRNA implication in cancer is represented
by the fact that miRNAs can be up- or down-regulated in malig-
nancies and, therefore, respectively referred to as oncogenes or
tumor suppressors, sometimes even if there is no evidence for their
causative role in tumorigenesis (Esquela-Kerscher and Slack, 2006;
Croce, 2009). The more characterized and first identified tumor-
suppressor miRNA is represented by the miR-15/16 cluster, deleted
in 68% of Chronic Lymphocytic Leukemia (CLL) patients carrying
a 13q14.3 translocation (Calin et al., 2002). A mouse model that
mimics the minimal deletion region 13q14.3 or that specifically
deletes the miR-15a/16-1 cluster exhibited a full spectrum of CLL-
associated phenotypes, consistent with the miR-15a/16-1 locus
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FIGURE 1 | Signaling pathways and new therapeutic targets for
ovarian cancer. Despite many efforts in these last few years, clinical
responses to curative chemotherapy in ovarian cancer remain very low
and have merely led to improvements in the survival of patients.
Therefore, new different drugs and combination treatments have been
identified and are now entering clinical trials to test new therapeutic
possibilities. In the figure, we depicted in blue some of the most
important new or promising clinical targets in ovarian cancers. Many
other different therapeutic approaches have also been taken and here
not depicted, such as new cytotoxic agents (trabectedin, patupilone,
canfosfamide), anti-folate transporter 1 inhibitor (farletuzumab), PARP
inhibitor (olaparib).
having a tumor-suppressor role in the B-cell lineage (Klein et al.,
2010). An example of oncogenic miRNA is miR-155, which is
overexpressed in different types of B-cell malignancies, including
pediatric Burkitt’s lymphoma, Hodgkin’s lymphoma, aggressive
CLL, and diffuse large B-cell lymphoma (DLBCL) (Croce, 2009).
Transgenic expression of miR-155 is sufficient to initiate lym-
phomagenesis in mice (Costinean et al., 2006). Another aspect
to be considered is the high context-dependent activity of miR-
NAs. The same miRNA can act as an oncogene in one type of
cells and as a tumor suppressor in another due to different tar-
gets and mechanisms of action (Croce, 2009). Accordingly, this
miRNA may be found upregulated in some cancer types, where
it acts as oncogene, but downregulated in other cancers, indica-
tive of tumor-suppressor function. An example is represented by
miR-222/221 cluster that is overexpressed in breast, lung, or liver
cancers where targets important tumor suppressors such as PTEN,
p27, p57, while the same cluster is downregulated in erythroblastic
leukemias where target c-KIT oncogene (Garofalo et al., 2012). The
causes of the widespread misexpression of miRNAs in cancers can
be explained by different mechanisms including: (a) chromoso-
mal alterations of the miRNA genes, (b) DNA point mutations,
(c) epigenetic mechanisms, (d) transcriptional modulation, or
(e) genetic and epigenetic alterations in the transcriptional and
post-transcriptional machinery responsible for miRNA produc-
tion (Di Leva and Croce, 2010). Despite the large scientific interest
for the understanding of miRNA dysregulation in cancer, the
most daunting task is still the discovery of the biological func-
tions of the dysregulated miRNAs in cancer. One main rule is
emerged from the vast literature about the biological activity of
miRNAs in cancer: oncogenic miRNAs repress the expression of
tumor-suppressor genes, while tumor-suppressor miRNAs repress
the expression of oncogenes (Esquela-Kerscher and Slack, 2006).
For example, overexpression of the oncogene, miR-21, frequently
highly expressed in solid and hematologic malignancies, represses
strong tumor suppressors as PTEN or programed cell death 4
(PDCD4) while loss of the tumor-suppressor miR-15a/miR-16-
1 in CLL induces the overexpression of the anti-apoptotic BCL2
(Cimmino et al., 2005; Meng et al., 2007; Asangani et al., 2008).
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Table 1 | Common miRNAs altered in human cancers.
MicroRNA Expression in cancer Function Mechanism of deregulation Targets
Let-7a-2 Down in breast, lung, colon,
ovarian, and stomach cancer
Tumor suppressor Repressed by MYC KRAS, HMGA2, MYC, DICER, BCLXL,
IMP-1, CDC34, IL6
miR-15/16 Down in CLL, prostate cancer,
and pituitary adenomas
Tumor suppressor Genomic loss, mutated, activated by
p53
BCL2, COX2, CHECK1, CCNE1,
CCND1, CCND2, BMI-1, FGF2, FGFR1,
VEGF, VEGFR2, CDC25a
miR-29 family Down in AML, CLL, lung and
breast cancer, lymphoma,
hepatocarcinoma,
rhabdomyosarcoma
Tumor suppressor Genomic loss, activated by p53,
repressed by MYC
CDK6, MCL1, TCL1, DNMT1,
DNMT3a, DNMT3b
miR-34 family Down in colon, lung, breast,
kidney, and bladder cancer
Tumor suppressor Repressed by MYC SIRT1, BCL2, NOTCH, HMGA2, MYC,
MET, AXL. NANOG, SOX2, MYCN,
SNAIL
miR-26a Down in liver cancer Tumor suppressor Repressed by MYC CCND2, CCNE2
miR-200 family Down in aggressive breast and
ovarian cancer
Tumor suppressor Repressed by ZEB1/2 ZEB1, ZEB2, BMI-1, SUZ-12, FN1,
LEPR, CTNNB1, JAG1, MALM2,
MALM3, p38 alpha
miR-155 Up in high risk CLL, AML, breast,
lung, colon cancer, and
lymphoma
Oncogene Activated by NF-KB SOCS1, BACH1, MEIS1, ETS1,
FOXO3A, hMSH2, hMSH6, hMLH1,
SMAD5, WEE1, SHIP1, CEBPB
miR-21 Up in lung, breast, pancreas
stomach, ovary prostate cancer,
and CLL, AML, glioblastoma,
myeloma
Oncogene Activated by IL6, GF1alpha PTEN, TPM1, PDCD4, SPRY1, TIMP3,
RECK
miR-221/-222 Up in invasive ductal carcinoma,
lung cancer, hepatocellular
carcinoma, papillary thyroid
cancer
Oncogene Activated by MET in lung cancer;
repressed by ERalpha in breast;
activated by PLZF in melanoma;
activated by NF-Kb and cJun in
prostate cancer and glioblastoma cells
p27(Kip1), p57(Kip2), PTEN, TIMP3,
FOXO3A, ERalpha, KIT, TRSP1, DICER,
APAF1, PUMA, PTPµ
miR-17/92 Up in lung, breast, colon Oncogene Activated by E2F1 and MYC PTEN, BIM, HIF1, PTPRO, p63, E2F2,
E2F3, TSP-1, CTGF, p21(WAF1), JAK1,
SMAD4, TGFbetaII, MnSOD, GPX2,
TRXR2
Another common mechanism of miRNA activity in cancer cells is
their involvement in negative and positive feedback loops. This is
well illustrated by miR-146a, which is transactivated by the NF-
κB pathway and negatively feeds back on this signaling cascade
by targeting two upstream activators of the pathway, TRAF6 and
IRAK1 (Taganov et al., 2006). Interestingly, deletion of miR-146a
in mice results in increased activity of NF-κB in splenocytes and the
consequent development of NF-κB-dependent myeloid sarcomas
(Zhao et al., 2011). Finally, a particularly intriguing, but poorly
understood, aspect of the biology of miRNAs is their presence in
numerous body fluids, including serum, plasma, saliva, and amni-
otic fluid (Cortez et al., 2011). miRNAs in serum correlate with the
presence of hematologic malignancies and solid tumors and have
been reported to be of value for early detection of various types
of cancer, preceding diagnosis by conventional methods (Boeri
et al., 2011). The question of whether tumor-associated miRNAs
detected in circulation results from tumor cell death and lyses,
or instead from secretion by tumor cells remains unanswered. It
has been reported that the profile of secreted miRNAs does not
reflect the miRNA composition of the primary tumor, suggesting
active regulation of miRNA release or cellular retention (Collino
et al., 2010). Generally, miRNAs are present in biological fluids
as lipoprotein complexes, small membranous vesicles known as
exosomes or as non-vesicular Ago2 ribonucleoprotein complexes
(Arroyo et al., 2011).
miRNA AS DIAGNOSTIC TOOLS IN OVARIAN CANCER
Genome-wide miRNA profiling techniques have shown their util-
ity to classify tumors based on their origin and differentiation state
and to help in diagnosis and prognosis. As discussed above, several
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reports have already shown this miRNA feature for several tumor
types. The first report of miRNA dysregulation in ovarian can-
cer came from our laboratory in 2007: miRs expression profiles
were shown to discriminate between ovarian-cancer specimens
and normal ovaries (Iorio et al., 2007) (Table 2). miR-200a and
miR-141 were identified as highly upregulated in cancer, whereas
miR-199a, miR-140, miR-145, and miR-125b1 were most signifi-
cantly downregulated. In this study, specific miRNA deregulation
was also used to differentiate the histological subtypes of ovarian
carcinomas. For example, miR-200a and miR-200c were upregu-
lated in all subtypes (mucinous, endometrioid, and clear cells),
miR-200b and miR-141 were upregulated in serous as well as
endometrioid carcinomas, and miR-21, miR-203, and miR-205
were upregulated only in endometrioid carcinomas. Indeed, miR-
145 was downregulated in serous and clear-cell carcinomas, while
miR-222 was downregulated in both endometrioid and clear-cell
carcinomas. Later, Coukos laboratory highlighted a large down-
regulation of miRNAs in ovarian-cancer cell lines and cancer
specimens (Zhang et al., 2008). The authors identified a different
expression of 44 miRNAs between early- and late-stage ovar-
ian cancer with a complete down-regulation for all miRNAs in
late-stage tumors. These signatures included three known tumor-
suppressors miRNAs, mir-15a, mir-34a, and mir-34b. The authors
also showed that the region containing the up-regulated miR-182
was amplified in 28.9% of ovarian carcinomas, whereas, miR-15a
was deleted in 23.9% of ovarian carcinomas, as previously also
shown for CLL (Calin et al., 2002). Further genome-wide miRNA
studies were performed and all defined a large miRNA dysregu-
lation in ovarian tumors. To date, Nam et al. (2008) identified 23
aberrantly expressed miRNAs in at least 60% of ovarian-cancer
samples with miR-21 as the most upregulated (85% samples)
and miR-125b (95% samples) most down-regulated miRNAs.
Yang et al. (2008a) identified 36 miRNAs differentially expressed
between normal ovarian cells and tumors, including miR-199a∗,
miR-214, miR-200a which were found upregulated in 53, 56, and
43% tumor tissues respectively, and associated with high-grade
and late-stage tumors. miR-100 was identified instead as down-
regulated in 76% of tumors. In contrast with these data, Eitan
et al. (2009) identified miR-200a, miR-34a, and miR-449b as the
most down-regulated miRNAs in the advanced (stage III) ovar-
ian tumors with miR-200a associated in the early-stage disease
to an improved overall survival. miR-200a was also identified as
predictor of favorable outcome in another profiling study of a
cohort of 55 advanced ovarian tumors (Hu et al., 2009). Another
member of the miR-200 family, miR-200c, was also identified by
Marchini et al. (2011) as associated with progression-free survival,
overall survival, or both in multivariate analysis of stage I ovar-
ian cancers. In a later study in 2011, The Cancer Genome Atlas
(TCGA) provided the first comprehensive molecular classifica-
tion of a large cohort of high-grade serous ovarian carcinomas by
integrated analyses of multidimensional data, including miRNA
expression profiles, to identify molecular abnormalities that influ-
ence ovarian-cancer pathophysiology, affect outcome, and consti-
tute therapeutic targets. Transcriptomic analyses identified four
molecular subtypes of ovarian cancer, not significantly associated
to survival, named Immunoreactive, Differentiated, Proliferative,
and Mesenchymal based on the enrichment of specific genes in the
subtype. miRNA expression instead differentiated the tumor spec-
imens in three main subtypes where miRNA subtype 1 overlapped
with the mRNA Proliferative subtype and miRNA subtype 2–3
overlapped with the mRNA Mesenchymal subtype. The subtype 1
was associated with worse patient survival as compared to the other
two subtypes. A recent elaboration of the TCGA data has been per-
formed by Dr. Zhang laboratory (Yang et al., 2013). The authors
showed that integrated analysis of miRNAs and transcriptome is
able to group the transcriptional subtypes into two more clini-
cally relevant subtypes, one mesenchymal and one epithelial. The
analyses highlights the important role of a miRNA regulatory net-
work consisting of eight key miRNAs for the mesenchymal subtype
including miR-141 and miR-200, miR-29c, miR-101, miR-506, and
miR-128.
MicroRNAs signatures have demonstrated their potential as
diagnostic tool also in the ability to predict the clinical response
to chemotherapy. In 2008, again in collaboration with our labo-
ratory, Dr. Zhang’s group identified the involvement of let-7i in
response to cisplatin for the treatment of ovarian cancer (Yang
et al., 2008b). Another study performed by Eitan et al. (2009) ana-
lyzed the miRNA correlation to platinum-based chemotherapy
response in stage III patients. By comparing the miRNA expres-
sion between patients that achieved complete response with no
recurrence within 6 months of the end of treatment and patients
that progressed really rapidly after treatment, the authors iden-
tified seven miRNAs to be significantly differentially expressed,
including hsa-miR-27a, 23a, miR-378. The differential expression
of these three miRNAs between sensitive and resistant tumors was
also observed in the subset of stage III patients treated by the
combined paclitaxel/carboplatin treatment. Leskelä et al. (2010)
demonstrated instead that miR-200 family showed a significant
association with treatment response to paclitaxel–carboplatin reg-
imen: women lacking complete response to paclitaxel–carboplatin
regimen had tumors with significantly lower miR-200c levels
than the ones who had achieved complete response; in addi-
tion, higher expression of miR-200c was associated with lower
relapse/progression rates. Currently, a combined treatment of car-
boplatin/paclitaxel has been adapted as the standard treatment
for women with advanced epithelial ovarian cancer (EOC) (Hiro
et al., 2010). However, many patients with ovarian cancer which
initially respond to chemotherapy eventually relapse with drug-
resistant disease (Hassan et al., 2011). Acquired chemoresistance
is a major obstacle for successful cancer treatment. Based on the
correlation between drug response and miRNA expression, many
studies have tried to manipulate the mechanisms responsible for
chemoresistance by altering the levels of miRNAs. For example,
Liu et al. (2012) have demonstrated that a chimera composed
of a MUC1 aptamer and let-7i can efficiently deliver let-7i into
paclitaxel/cisplatin resistant ovarian tumor cells and subsequently
resensitize to the apoptotic role of the drugs the ovarian malignant
cells. Prislei et al. (2013) showed that overexpression of miR-200c
repressed the expression of level of class III β-tubulin (TUBB3),
a factor associated with drug resistance and poor prognosis in
ovarian cancer, and increased sensitivity to paclitaxel and cis-
platin. Same results were also obtained by Cochrane et al. (2010)
which showed that restoration of miR-200c increases sensitivity to
microtubule-targeting agents and mitigates invasiveness by 85%.
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Table 2 | miRNA profiling studies in human epithelial ovarian cancers.
Reference Number of samples/subtypes Method of analyses Main findings
Iorio et al. (2007) 15 Normals/69 tumors
31 Serous/8 endometrioid/4
clear cells/9 poorly
differentiated/1 mucinous
miRNA microarray Ovarian cancer-specific miRNA signature
Subtypes specific miRNA signature
Epigenetic mechanism responsible for their aberrant
expression
Yang et al. (2008a) 10 Tumors and 10 “normal”
HIOSE cell line
miRNA microarray Ovarian cancer-specific miRNA signature
miR-214 induces cell survival and cisplatin resistance
through targeting PTEN
Laios et al. (2008) 3 Primary serous/3 recurrent
serous tumors
qRT-PCR miR-9 and miR-223 can be biomarkers in recurrent
ovarian cancer
Nam et al. (2008) 22 Serous tumors/8 normals miRNA microarray Ovarian cancer-specific miRNA signature
Zhang et al. (2008) 106 Tumors
109 Tumors
76 Tumors
504 Tumors
miRNA microarray,
aCGH,
affymetrix cDNA microarray,
tissue array,
miRNAs are downregulated in malignant transformation
and tumor progression
Genomic copy number loss and epigenetic silencing
account for miRNA dysregulation
96 Tumors qPCR validation
Dahiya et al. (2008) 34 Tumors and HOSE-B cell line miRNA microarray Ovarian cancer-specific miRNA signature
Sorrentino et al. (2008) Drug-resistant vs. wild-type
cancer cell lines
miRNA microarray Paclitaxel and cisplatin resistance is associated with a
specific miRNA fingerprint
Yang et al. (2008b) 69 Tumors (42 sensitive/27
resistant)
miRNA microarray Let-7i is a modulator of platinum-based chemotherapy
Let-7i is a biomarker to predict chemotherapy response
and survival
Boren et al. (2009) 16 Ovarian cancer cell lines miRNA microarray miRNA signature associates to cell line drug response
Wyman et al. (2009) 33 Tumors/HOSE-B cell line Deep sequencing Ovarian cancer-specific miRNA signature
Subtypes specific miRNA signature
Eitan et al. (2009) 19 Tumors (stage I)/38 tumors
(stage III)
miRNA microarray miRNA signature during progression
miRNA expression associated with response to
platinum-chemotherapy
Hu et al. (2009) 55 Advanced-stage tumors miRNA microarray miR-200b-429 are biomarkers for ovarian cancer outcome
Lee et al. (2009) 33 High-grade serous tumors
2 Low-grade serous tumors
miRNA microarray No abnormalities in miRNA expression correlated to
BRCA1/2 status
2 Serous borderline tumors miR-34c and miR-422b are prognostic biomarkers
3 Normal fallopian tubes
Nagaraja et al. (2010) 10 Human clear-cell ovarian
cancer cell lines and 1 normal
ovarian surface epithelial cultures
Deep sequencing Clear-cell ovarian cancer-specific miRNA signature
miR-101 inhibits mTOR pathway and increases rapamycin
sensitivity
Creighton et al. (2010) 8 Serous tumors
4 Serous cancer cell lines
4 NOSE cell lines
Deep sequencing miR-31 is downregulated in cancer
Reduced levels of miR-31 are correlated with defects in
the p53 pathway
Vaksman et al. (2011) 21 Tumors (13 effusions/
8 primary tumors)
miRNA microarray miRNA signatures for the primary tumors and effusions
Kim et al. (2010) 103 Tumors miRNA microarray miRNA signature is correlated with clinico-pathological
parameters (subtype, grade, survival)
Marchini et al. (2011) 144 Tumors (stage I) miRNA microarray Ovarian cancer-specific miRNA signature
miR-200c is a predictor of survival and relapse
Cancer Genome Atlas
Research Network (2011)
489 Serous tumors miRNA microarray Global analyses of mRNA expression, miRNA expression,
promoter methylation, and DNA copy number
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Two other studies reported that miR-182 and miR-125b conferred
resistance to cisplatin, possibly by their anti-apoptotic activity due
to the repression of two important tumor suppressors, PDCD4
and Bcl-2 antagonist killer 1 (Bak1), respectively (Kong et al., 2011;
Wang et al., 2013).
Because the majority of ovarian-cancer patients are diagnosed
with advanced-stage disease, identification of early tumor is essen-
tial to improve prognosis and therapy. One of the best ways to
early diagnose, aid prognosis, and predict therapeutic response
is by using diagnostic or prognostic serum and tissue biomark-
ers. Unfortunately, there are not many reliable serum biomarkers
for ovarian-cancer currently used in the clinic, and tissue-based
markers require an invasive procedure to obtain samples. There-
fore, new efforts are needed to identify new serum markers to aid
in the screening process. The ability to profile miRNAs in circula-
tion have shown a non-invasive opportunity to identify promising
alternative approaches to the current strategies for ovarian-cancer
surveillance and early diagnosis. In this context, by using serum
samples from patients with various stages of ovarian cancer, Tay-
lor and Gercel-Taylor (2008) showed that 46% of miRNAs in the
exosomes were the same as those in the primary tumors. Twelve
miRNAs were present at a higher proportion in malignant cells (es:
mir-155, -29), while 31 were present at elevated levels exclusively
in exosomes (es: miR-203, -205). A study from our laboratory
identified 23 miRNAs differentially expressed in serum of patients
with ovarian cancer; only 10 of these miRNAs were in common
with miRNAs that have been previously published in the litera-
ture as part of the miRNA signatures of ovarian cancer (including
mir-21) (Resnick et al., 2009). In another study, the levels of four
miRNAs (miR-200a, b, c, and miR-182) were identified as differ-
entially expressed between the serum of 28 patients with serous
ovarian cancer and healthy age-matched volunteers (Kan et al.,
2012). miR-200c was the most differentially expressed and a com-
bination of miR-200b and miR-200c gave the best predictive power
for serous ovarian cancer. A different approach was instead taken
by Vaksman et al. (2011) who analyzed the miRNA expression pro-
files of primary ovarian cancers and effusions from patients with
disease spread beyond the ovary in order to define a new para-
meter for metastatic dissemination. The authors identified three
groups of miRNAs: (1) highly expressed in primary ovarian cancer
and effusions; (2) overexpressed only in primary ovarian cancer;
and (3) overexpressed only in effusions. miR-210, -182, and -99a
were significantly overexpressed in effusions compared to primary
tumors, whereas hsa-miR-145 was significantly overexpressed in
primary carcinomas. Overall, the above studies provided useful
biomarkers information for ovarian cancer. The large heterogene-
ity of the results, based on differences in the samples analyzed and
technology applied, highlights that additional studies are needed
to define predictive and reliable miRNA signatures that can find a
clinico-pathological application.
CAUSE OF miRNA DYSREGULATION IN OVARIAN CANCER
An important aspect of miRNA biology in ovarian cancer that
has been taken in consideration during the last few years is the
cause of the large dysregulation of miRNAs in cancer that pro-
filing studies have shown. First, chromosomic alterations have
been identified for several miRNA genes. As previously described,
Coukos’s laboratory identified a consistent amplification of miR-
182 region and deletion of miR-15 in ovarian carcinomas (Zhang
et al., 2008). The same authors also showed a remarkably high fre-
quency of miR-210 gene copy deletions in ovarian-cancer patients,
and that gene copy number correlated with miR-210 expression
levels (Giannakakis et al., 2008). Loss of heterozygosity at the let-
7a-3/let-7b and mir-143/mir-145 loci was also detected in 50 and
22% of 90 ovarian carcinomas, respectively (Bearfoot et al., 2008).
The authors analyzed also the somatic mutations status of a∼500-
bp genomic region surrounding 10 ovarian-cancer-implicated
miRNA genes (let-7a-2, let-7a-3, let-7b, miR-10b, miR-125b-1,
miR-125b-2, miR-143, miR-145, miR-200c, miR-206). Despite
analyzing a large cohort of primary tumors, no somatic muta-
tions were detected at the genomic regions corresponding to the
primary, precursor, or mature miRNAs in any of the miRNA genes
studied, suggesting that somatic mutations may not be a common
mechanism of miRNA inactivation in ovarian cancer. Another
mechanism that has been analyzed to explain the miRNA dys-
regulation in ovarian cancer is the altered levels or presence of
mutations in the main enzymes of the miRNA biogenesis machin-
ery, such as Dicer and Drosha. In fact, aberrations of the main
proteins that are involved in miRNA processing will lead to changes
in miRNA expression and ultimately to alterations of miRNA-
mediated gene regulation. A work published in 2010 evaluated a
decrease of 60 and 51% in the levels of Dicer and Drosha mRNAs,
respectively, in 39% of ovarian-cancer tissues analyzed (Merritt
et al., 2008). The authors also showed that, neither Dicer nor
Drosha mRNA levels were significantly associated with age, tumor
grade, or response to chemotherapy but low Dicer and Drosha
mRNA levels were, however, significantly associated with advanced
tumor stage or suboptimal cytoreductive surgery, respectively.
Moreover,women whose tumor had low levels of Dicer and Drosha
mRNA showed a reduced overall survival, indicating a clinical rel-
evance for an alteration in the levels of Dicer and Drosha mRNAs
in ovarian-cancer cells. Same conclusion were also obtained by
another study performed by Pampalakis et al. (2010) who observed
a marked down-regulation of Dicer expression in ovarian tumors
of higher grade and higher stage. Unfortunately, the basis of the
observed down-regulation of Dicer or Drosha expression in ovar-
ian tumors is unknown. We may speculate that the presence of a
large CpG island at Dicer genomic loci indicates that genomic
DNA methylation may account for Dicer down-regulation in
ovarian tumors, but further investigations are needed.
An intriguing report came from Dr. Huntsman laboratory
which discovered the presence of recurrent somatic missense
mutations of DICER1 in non-epithelial ovarian tumors (Heravi-
Moussavi et al., 2012). These mutations were predominantly
restricted to a specific subset of non-epithelial ovarian tumors
and highly prevalent (60%) in Sertoli–Leydig cell tumors. The
recurrent and focal nature of these mutations and their restriction
to non-epithelial ovarian tumors suggested a common oncogenic
mechanism associated with a specific altered DICER1 function
that is selected during tumor development in these cell types.
The localized and focal pattern of mutations is typical of dom-
inantly acting oncogenes, like KRAS and BRAF. The absence of
loss of heterozygosity that is seen in association with germline
DICER1 mutations provides further evidence against a role for
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DICER1 as either a haploinsufficient or a two-hit recessive tumor
suppressor in this non-EOC. We can imagine that the new mutated
DICER1 alleles produce viable protein that is able to create a differ-
ent miRNA profile with oncogenic potentials. As well as for Dicer
and Drosha, Vaksman, and collaborators suggested a role in tumor
progression of ovarian cancer for the Ago family members, Ago1
and Ago2. Specifically, the authors identified an overexpression
of Ago1 and Ago2 in the peritoneal effusions compared with pri-
mary ovarian carcinomas, and high levels of Ago2 mRNA in solid
metastases compared with primary tumors Vaksman et al., 2012).
Based on high-throughput results, Zhang et al. (2008) showed
that if deletions occur in up to 15% of genomic loci harboring
miRNAs that are downregulated, at least one-third of down-
regulated miRNAs may be silenced by epigenetic alterations. Iorio
et al. (2007) showed that 11 miRNAs, including miR-21, miR-203,
miR-146b, miR-205, miR-30-5p, and miR-30c as the most signifi-
cantly induced, are differentially expressed after treatment with the
demethylating agent 5-AZA. Lu et al. (2007) showed that let-7a-3 is
methylated in EOC, and low expression of let-7a is associated with
poor prognosis. Epigenetic silencing of miR-130b through hyper-
methylation of the adjacent CpG island has been also identified
and low expression of miR-130b was correlated to ovarian cancer
with high stage and multidrug resistance (Yang et al., 2012). In
fact, treatment of ovarian-cancer cells with demethylating agents
increased miR-130b levels and decreased the IC50 of paclitaxel and
cisplatin treatment. Complementary mechanisms, including tran-
scriptional regulation, may also cooperate in miRNA deregulation
of ovarian cancer. An important example of miRNA transcrip-
tional control in ovarian cancer is represented by the miR-200
family, which has been shown highly modulated in ovarian can-
cer. The miR-200 family contains miR-200a, miR-200b, miR-200c,
miR-141, and miR-429 which are arranged in two clusters in the
human genome. miR-200a, miR-200b, and miR-429 are located on
chromosome 1, while miR-200c and miR-141 are on chromosome
12. ZEB1/2, two transcription factors involved in the mediation of
the epithelial to mesenchymal transition, can inhibit the expres-
sion of miR-200 family members by binding to the promoter of
both miR-200 clusters thereby blocking transcription (Gregory
et al., 2008). In turn, over expression of miR-200 family members
repress ZEB1/2 levels, and leads to higher levels of E-cadherin and
an epithelial phenotype (Burk et al., 2008). In fact, Park et al.
(2008) have shown a positive correlation in the expression of
E-cadherin with the expression of miR-200c in ovarian-cancer
tissues. We can summarize that cancer cells after being triggered
by molecular signaling, such as TGF-β or PDGF-D, increases their
levels of ZEB1/2 which in turn decrease the expression of miR-
200 and induce EMT. An interesting example of multi mechanism
control of miRNA expression in ovarian cancer is represented by
the miR-34 family. miR-34 clusters are part of the transcriptional
program activated by p53 (He et al., 2007). Mutational and loss of
TP53 function is one of the most frequent genetic abnormalities
in ovarian cancer and is observed in 60–80% of both sporadic and
familial cases (Bast et al., 2009). In accordance with the loss of
TP53, miR-34 members (miR-34a, b, c) have been found strongly
repressed in ovarian cancer: miR-34a expression is decreased in
100% and miR-34b∗/c in 72% of EOC with p53 mutation (Corney
et al., 2010). However, miR-34a was also downregulated in 93% of
tumors with wild-type p53, indicating the presence of other mech-
anisms implicated in the suppression of miR-34a gene. In fact, the
authors identified methylation and reduced copy number at the
mir-34a gene in 27 and 39% of ovarian-cancer tissues, respectively.
CONCLUSION
In the next 5 years we could witness a very exciting periods for
drug development in ovarian cancer since the introduction of cis-
platin into chemotherapy. The discovery of aberrantly expressed
miRNAs in ovarian cancer have defined new pathways in ovarian
tumorigenesis and progression. miRNA expression profiles in tis-
sues and biological fluids can potentially be used for the detection
and surveillance of ovarian cancer. But miRNAs have also shown
their efficacy in altering the sensitivity to traditional drugs. There-
fore, targeted therapies should be accelerated by the delivery of
specific miRNAs or miRNA inhibitors, which have been shown to
be effective in ovarian-cancer cells.
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